Global HIV diagnostics test market is estimated to be valued at USD 4.44 BN in 2024 and is expected to exhibit a CAGR of 9.2% during the forecast period (2024-2031). The HIV diagnostics test market has seen significant growth over the past few decades and is expected to grow substantially going forward. This is mainly due to the rise in number of people impacted by HIV/AIDS globally. Early detection of HIV infection plays a vital role in controlling the spread of the disease as well as improves the quality of life of infected individuals with timely treatment initiation. Advancements in diagnostic technologies have enabled development of rapid, simple, and point-of-care HIV testing kits which have improved accessibility and uptake of HIV testing services across all settings.

Market Dynamics:

The global HIV diagnostics test market growth is driven by the rising prevalence of HIV/AIDS infections worldwide. According to WHO, around 38 million people were living with HIV in 2020. Favorable government initiatives and regulations regarding HIV/AIDS diagnosis & management also boost the market growth. However, lack of awareness about HIV/AIDS in developing nations and social stigma associated with the disease hamper widespread adoption of diagnostic tests. On the other hand, ongoing R&D towards development of novel diagnostic platforms with enhanced sensitivity and shorter turn-around-time presents multiple growth opportunities in the market.

Key Features of the Study:

• This report provides in-depth analysis of the global HIV diagnostics test market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global HIV diagnostics test market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes Abbott, Bio-Rad Laboratories Inc., Hologic Inc., Siemens Healthineers, F. Hoffmann-La Roche Ltd., Beckman Coulter Inc., OraSure Technologies Inc., Becton Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems Inc., Zyomyx Incorporation, Bristol –Myers Squibb, Janssen Pharmaceutica NV, QIAGEN N.V., and ViiV Healthcare Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global HIV diagnostics test market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global HIV diagnostics test market.

Market Segmentation

• Product:
  • Assay Kit
  • Consumables
• Test Type:
  • Antibody Test
  • Antigen/antibody tests
  • Nucleic Acid Test
• End User:
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Homecare Settings
  • Others
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Abbott
  • Bio-Rad Laboratories Inc.
  • Hologic Inc.
  • Siemens Healthineers
  • Hoffmann-La Roche Ltd.
  • Beckman Coulter Inc.
  • OraSure Technologies Inc.
  • Becton Dickinson and Company
  • Merck KGaA
  • Chembio Diagnostic Systems Inc.
  • Zyomyx Incorporation
  • Bristol –Myers Squibb
  • Janssen Pharmaceutica NV
  • QIAGEN N.V.
  • ViiV Healthcare Ltd.